Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus

Stopped early · Not applicable

Conditions studied: Barrett Esophagus, Gastroesophageal Reflux

In brief

The purpose of this research study is to assess how safe, effective (how well it works), and tolerable (to put up with) the drug Zegerid is in reducing reflux episodes in patients who have both gastroesophageal reflux disease (GERD) and Barrett's esophagus. Zegerid has been approved by the US Food and Drug Administration (FDA) for the treatment of GERD. The investigators hope to learn the effectiveness of Zegerid for reducing the amount of acid reflux patients are experiencing in the esophagus (swallowing pipe).

Key facts

Study ID

NCT01129778

Run by

Stanford University

People needed

27

Starts

2009-11-01

Expected to finish

2010-12-01

Last updated by the study team

2017-06-06

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Inclusion criteria include adult men and women (aged <=18 years) with previously established, biopsy-proven diagnosis of BE (any length intestinal metaplasia without dysplasia or adenocarcinoma)

You may not qualify if…

• Exclusion criteria include a history of esophageal, gastric, or duodenal surgery (including antireflux surgery or endoscopic antireflux procedures), except for simple ulcer closure
• Zollinger-Ellison syndrome
• Endoscopic evidence or suspicion of a pathologic or infiltrative process in the stomach
• Positive for H. pylori.

Where it is running

• Stanford University School of Medicine — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.